Compare Inovio Pharmaceuticals Inc (INO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Lamb Weston Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Lamb Weston Holdings Inc trades at $47.87 (market cap $6.81B). The key difference: Lamb Weston Holdings Inc is far larger — about 60.7× Inovio Pharmaceuticals Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Lamb Weston Holdings Inc for 66 Days on average.
| INO | LW | |
|---|---|---|
Market Cap | $112.19M | $6.81B |
Volume | 3,201,278 | 4,638,686 |
Sector | Health | Consumer Staples |
52-Week High | $2.60 | $66.57 |
52-Week Low | $0.66 | $38.48 |
Typical Hold Time | 43 Days | 66 Days |
Enterprise Value | $83.51M | $10.61B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Lamb Weston (LW) trades at $49.46, up 2.85% today, showing strong momentum with four consecutive earnings beats. The stock maintains a bullish technical signal with support at $49 and resistance at $50. Fundamentals show solid revenue growth from $4.1B in 2022 to $6.45B in 2025, though net margins compressed from 18.85% to 3.85%. Analyst consensus is mixed with 31.58% Buy ratings and a $53.71 price target, representing 8.6% upside potential.
LW offers potential through continued earnings outperformance and margin recovery initiatives, but faces risks from profit margin volatility and ongoing legal scrutiny. The stock's current valuation at 27x P/E appears reasonable given growth prospects, though investors should monitor execution on the Focus to Win cost-saving strategy and resolution of fiduciary investigation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
